A call for cost-effectiveness analysis for biologic therapies in chronic rhinosinusitis with nasal polyps

Abstract

Objective: To identify the need for cost-effectiveness analysis of biologic therapies in the treatment of chronic rhinosinusitis (CRS).

Data sources: Clinical trials of monoclonal antibodies (omalizumab, benralizumab, mepolizumab and dupilumab) for nasal polyposis or chronic rhinosinusitis published on PubMed.

Study selections: Clinical trials of biologic therapies in CRS and nasal polyposis.

Results: No cost-effectiveness analyses of biologic therapies in CRS have been performed.

Conclusion: As more clinical trials of biologic therapies for CRS are conducted, there is a need for cost-effectiveness analysis. Future analyses should consider these therapies as part of medical therapeutic options compared with surgery. To increase generalizability, analyses should include samples from allergy and primary care clinics rather than only otolaryngology clinics.